Real-life data – a characteristic of RA in patients with cardiovascular diseases on the background of treatment with biological agents
PDF BG/EN

Keywords

rheumatoid arthritis
cardiovascular diseases
biologic agents
real-life data

How to Cite

[1]
Shivacheva, T. 2019. Real-life data – a characteristic of RA in patients with cardiovascular diseases on the background of treatment with biological agents. Revmatologiia (Bulgaria). 27, 3 (Oct. 2019), 10-17. DOI:https://doi.org/10.35465/27.3.2019.pp10-17.

Abstract

Purpose: The purpose of this study is to analyze real-life data in order to characterize patients with RA and cardiovascular diseases that are treated with biological agents. Material and Methods:  In a retrospective study, data from real clinical practice were analyzed in 195 patients with seropositive RA, which are being treated with biological agents. Results: In patients with existing CVD, significantly higher mean ESR values ​​(23.95 vs. 19.31, p = 0.031) and CRP (6.41 vs. 3.36, p = 0.004) were detected over the period of the study period  of treatment. In contrast to the laboratory parameters, mean values of clinical parameters of RA - TJC, SJC and VAS clinical sings did not show a significant difference in patients with and without CVD. The time average value of DAS28 (ESR) during the study period was significantly higher in patients with CVD (3.7 vs. 3.39, p = 0.002) compared to those without CVD. DAS28 (CRP) shows the same trend. In patients with CVD, the time average value of the follow-up indicator was 3.21, and in patients without CVD, 2.88 (p <0.001). Conclusion: The results of this study, in PA patients conducting treatment with biological agents in the real life, outside of the clinical study conditions, demonstrate that independently of treatment, patients with CVD continue to maintain higher background inflammation. An optimization of therapeutic behavior in real life is necessary to improve the long-term prognosis of these patients.

https://doi.org/10.35465/27.3.2019.pp10-17
PDF BG/EN

References

  1. Agca R, Heslinga SC, Rollefstad S, et al EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update Annals of the Rheumatic Diseases 2017;76:17-28.
  2. Amaya-Amaya, J., Sarmiento-Monroy, J. C., Mantilla, R.-D., Pineda-Tamayo, R., Rojas-Villarraga, A., & Anaya, J.-M. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunologic Research, 2013, 56(2-3), 267–286
  3. Bautista LE, López-Jaramillo P, Vera LM, Casas JP et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001 May; 19(5):857-61.
  4. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol.2018;17(1):83.
  5. Krishnan E, Hakkinen A, Sokka T, Hannonen P. Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis. 2005. September;64(9):1350–2.
  6. Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2016;27(2):136-140.
  7. Magen, E., Mishal, J., Paskin, J., Glick, Z., Yosefy, C., Kidon, M. et al. Resistant Arterial Hypertension Is Associated With Higher Blood Levels of Complement C3 and C‐Reactive Protein. The Journal of Clinical Hypertension, 2008, (10) 677-683.
  8. Pappas, D. A., Nyberg, F., Kremer, J. M., Lampl, K., еt al. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clinical Rheumatology, 2018, 37(9), 2331–2340.
  9. Smolen, J. S., Aletaha, D., & McInnes, I. B. Rheumatoid arthritis. The Lancet, 2016, 388(10055), 2023–2038.
  10. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003 Jun; 16(6):429-33.
  11. Tiippana-Kinnunen T, Kautiainen H, Paimela L, Leirisalo-Repo M. Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up. Scand J Rheumatol. 2013;42(6):451–6.
  12. Urman A, Taklalsingh N, Sorrento C, McFarlane IM. Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. Scifed J Cardiol. 2018;2(3):1000019.
  13. Widdifield, J., Paterson, J. M., Huang, A. and Bernatsky, S. Causes of Death in Rheumatoid Arthritis: How Do They Compare to the General Population?Arthritis Care Res, 2018, (70): 1748-1755.
  14. Widdifield, J., Abrahamowicz, M., Paterson, J. M., Huang, A., et al. Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. The Journal of Rheumatology, 2018, 180427.
  15. Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag. 2012,8:219-23.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.